Paul Tomasic, Head of European Healthcare at Houlihan Lokey, speaks to HealthInvestor on the M&A outlook for the sector in 2024. While overall deal activity was subdued in 2023, there have been signs of recovery, including good deal activity levels in selected subsectors within healthtech. This resilience can be attributed to the continued pressing need for efficiency improvements across healthcare systems and should lead to a more robust 2024.
Read the article on the HealthInvestor website.